PepGen (PEPG) – Investment Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of PepGen (NASDAQ: PEPG) in the last few weeks:

• 6/16/2026 – PepGen is now covered by Craig Hallum. They set a “buy” rating and a $11.00 price target on the stock.
• 6/7/2026 – PepGen was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/2/2026 – PepGen was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/30/2026 – PepGen was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/21/2026 – PepGen had its “buy” rating reaffirmed by HC Wainwright.
• 5/13/2026 – PepGen had its price target lowered by Wedbush from $5.00 to $4.00. They now have an “outperform” rating on the stock.
• 4/21/2026 – PepGen had its “sell (d-)” rating reaffirmed by Weiss Ratings.

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).